Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to -$1.1 million.

  • Puma Biotechnology's Net Cash Flow fell 1087.72% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year increase of 8.75%. This contributed to the annual value of -$15.4 million for FY2024, which is 294.90% down from last year.
  • Latest data reveals that Puma Biotechnology reported Net Cash Flow of -$1.1 million as of Q3 2025, which was up 86.53% from -$8.4 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Net Cash Flow ranged from a high of $25.2 million in Q3 2022 and a low of -$25.9 million during Q3 2021.
  • For the 3-year period, Puma Biotechnology's Net Cash Flow averaged around -$2.1 million, with its median value being -$1.4 million (2023).
  • In the last 5 years, Puma Biotechnology's Net Cash Flow plummeted by 3,078.04% in 2021 and then skyrocketed by 229.90% in 2023.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Net Cash Flow stood at -$816,000 in 2021, then plummeted by 115.56% to -$1.8 million in 2022, then surged by 229.90% to $2.3 million in 2023, then fell by 14.40% to $2.0 million in 2024, then plummeted by 1,087.72% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$8.4 million for Q2 2025, and -$6.2 million during Q1 2025.